<?xml version="1.0"?>
<case>
<name>Cadbury Schweppes Pty Ltd v Darrell Lea Chocolate Shops Pty Ltd (No 3) [2006] FCA 386 (7 April 2006)</name>
<AustLII>http://www.austlii.edu.au/au/cases/cth/FCA/2006/386.html</AustLII>
<citphrases>
<citphrase id="cp0.0" type=cited from="[2006] FCA 364">evidence</citphrase>
<citphrase id="cp0.1" type=cited from="[2006] FCA 364">whether survey evidence is admissible</citphrase>
<citphrase id="cp0.2" type=cited from="[2006] FCA 364">whether exception to the hearsay rule applies</citphrase>
<citphrase id="cp0.3" type=cited from="[2006] FCA 364">whether discretion should be exercised to exclude survey evidence</citphrase>
<citphrase id="cp0.4" type=cited from="[2006] FCA 364">non-compliance with practice note 11.</citphrase>
<citphrase id="cp1.0" type=cited from="[2006] FCA 363">evidence</citphrase>
<citphrase id="cp1.1" type=cited from="[2006] FCA 363">opinion evidence as to likely consumer behaviour excluded</citphrase>
<citphrase id="cp1.2" type=cited from="[2006] FCA 363">not outside the knowledge and experience of a trier of fact</citphrase>
<citphrase id="cp1.3" type=cited from="[2006] FCA 363">evidence of opinion as to ordinary human nature not admissible</citphrase>
<citphrase id="cp1.4" type=cited from="[2006] FCA 363">alternatively evidence would be excluded on discretionary grounds</citphrase>
<citphrase id="cp3.0" type=citing from="[2008] FCA 559">patents</citphrase>
<citphrase id="cp3.1" type=citing from="[2008] FCA 559">validity</citphrase>
<citphrase id="cp3.2" type=citing from="[2008] FCA 559">patent for (+)-enantiomer of the racemate, citalopram, and for method of obtaining that enantiomer</citphrase>
<citphrase id="cp3.3" type=citing from="[2008] FCA 559">patentee also held previous patent for the racemate</citphrase>
<citphrase id="cp3.4" type=citing from="[2008] FCA 559">both the racemate and the enantiomer, drugs for the treatment of depression</citphrase>
<citphrase id="cp3.5" type=citing from="[2008] FCA 559">(+)-citalopram claimed to be therapeutically more effective than citalopram</citphrase>
<citphrase id="cp3.6" type=citing from="[2008] FCA 559">challenge to validity of claim for (+)-citalopram</citphrase>
<citphrase id="cp3.7" type=citing from="[2008] FCA 559">construction of claim</citphrase>
<citphrase id="cp3.8" type=citing from="[2008] FCA 559">whether for (+)-enantiomer as an independently existing molecule or whether also for (+)-enantiomer when part of racemate</citphrase>
<citphrase id="cp3.9" type=citing from="[2008] FCA 559">whether claim for (+)-enantiomer anticipated by patent for citalopram</citphrase>
<citphrase id="cp3.10" type=citing from="[2008] FCA 559">whether (+)-enantiomer as an independent molecule was obvious</citphrase>
<citphrase id="cp3.11" type=citing from="[2008] FCA 559">australian test for obviousness</citphrase>
<citphrase id="cp3.12" type=citing from="[2008] FCA 559">application of that test to product claims for the (+)-enantiomer, and to method claim for the method of obtaining it</citphrase>
<citphrase id="cp3.13" type=citing from="[2008] FCA 559">lack of utility</citphrase>
<citphrase id="cp3.14" type=citing from="[2008] FCA 559">product claim for a dosage that, inter alia , was less than and more than a useful dosage range. held : (1) upon its proper construction, product claimed was the independently existing enantiomer; (2) the invention of the independently existing enantiomer was not anticipated by the patent for the racemate; (3) the australian "matter of routine" test for obviousness, when applied to the invention of the product, equated to the question whether those skilled in the art, as a matter of routine, would have had the goal of obtaining separate enantiomers in the expectation that one would be a desirable drug for the treatment of depression; (4) one of the product claims relating to dosage failed test of utility; (5) on the evidence, neither the (+)-enantiomer nor the method for obtaining it was obvious at the priority date.   patents</citphrase>
<citphrase id="cp3.15" type=citing from="[2008] FCA 559">extension of term</citphrase>
<citphrase id="cp3.16" type=citing from="[2008] FCA 559">patent for (+)-enantiomer of the racemate, citalopram, and for method of obtaining that enantiomer</citphrase>
<citphrase id="cp3.17" type=citing from="[2008] FCA 559">patentee also held previous patent for the racemate</citphrase>
<citphrase id="cp3.18" type=citing from="[2008] FCA 559">both the racemate and the enantiomer, drugs for the treatment of depression</citphrase>
<citphrase id="cp3.19" type=citing from="[2008] FCA 559">(+)-citalopram claimed to be therapeutically more effective than citalopram</citphrase>
<citphrase id="cp3.20" type=citing from="[2008] FCA 559">both cipramil (goods based on racemic citalopram) and lexapro (goods based on (+)-citalopram) entered in australian register of therapeutic goods (artg)</citphrase>
<citphrase id="cp3.21" type=citing from="[2008] FCA 559">application for extension of term of patent for (+)-citalopram</citphrase>
<citphrase id="cp3.22" type=citing from="[2008] FCA 559">commissioner of patents initially granted extension sought</citphrase>
<citphrase id="cp3.23" type=citing from="[2008] FCA 559">subsequently, following hearing before her delegate, decided to reduce term of extension on ground that "first regulatory approval date" was date when goods cipramil based on racemate had been entered in artg</citphrase>
<citphrase id="cp3.24" type=citing from="[2008] FCA 559">appeal by patentee</citphrase>
<citphrase id="cp3.25" type=citing from="[2008] FCA 559">opponent pharmaceutical company contending that no extension at all should have been granted because application for extension had been made outside six month period following date of first inclusion in artg of goods containing the (+)-enantiomer, namely, cipramil, of which the active pharmaceutical substance was the racemate</citphrase>
<citphrase id="cp3.26" type=citing from="[2008] FCA 559">questions of proper construction of patents act 1990 (cth) ss 70 , 71 , 77</citphrase>
<citphrase id="cp3.27" type=citing from="[2008] FCA 559">whether goods based on racemate "contain" individual enantiomer</citphrase>
<citphrase id="cp3.28" type=citing from="[2008] FCA 559">meaning of "first regulatory approval date" in s 70(5) of act. held : (1) cipramil contained pharmaceutical substance (+)-citalopram; (2) application for extension of term of patent had not been made within six months of first inclusion in artg of cipramil; (3) in circumstances, commissioner had lacked power to grant any extension to term of patent; (4) register of patents to be rectified by removal of particulars of extension.   patents</citphrase>
<citphrase id="cp3.29" type=citing from="[2008] FCA 559">infringement</citphrase>
<citphrase id="cp3.30" type=citing from="[2008] FCA 559">patent for (+)-enantiomer of the racemate, citalopram, and for method of obtaining that enantiomer</citphrase>
<citphrase id="cp3.31" type=citing from="[2008] FCA 559">generic company applying to therapeutic goods administration (tga) for registration of generic drug based on (+)-enantiomer of citalopram</citphrase>
<citphrase id="cp3.32" type=citing from="[2008] FCA 559">whether doctrine of "mechanical equivalents" or "non-essential integers" applicable to method of obtaining pharmaceutical compound</citphrase>
<citphrase id="cp3.33" type=citing from="[2008] FCA 559">generic pharmaceutical company producing generic drug only for purpose of applying for regulatory approval</citphrase>
<citphrase id="cp3.34" type=citing from="[2008] FCA 559">s 78(2) of patents act 1990 (cth).</citphrase>
</citphrases>
<citances>
<sentence id="cs0" from="[2008] FCA 559">I have not overlooked the decision of the High Court in Lee v The Queen (1998) 195 CLR 594 or Cadbury Schweppes Pty Ltd v Darrell Lea Chocolate Shops Pty Ltd (No 3) [2006] FCA 386 ; (2006) 229 ALR 179. I do not think, however, that they stand against the approach that I have taken above. </sentence>
<sentence id="cs1" from="[2008] ATMO 6">Cadbury Schweppes Pty Ltd v Darrell Lea Chocolate Shops Pty Ltd (No 3) [2006] FCA 386 A variety of market research documents were found admissible, but only insofar as they could be used for a non-hearsay purpose.</sentence>
</citances>
<legistitles>
<title id="l0">EVIDENCE ACT 1995 </title>
<title id="l1">EVIDENCE ACT 1995 - SECT 9 Effect of Act on other laws</title>
<title id="l2">EVIDENCE ACT 1995 - SECT 60 Exception: evidence relevant for a non-hearsay purpose</title>
<title id="l3">EVIDENCE ACT 1995 - SECT 77 Exception: evidence relevant otherwise than as opinion evidence</title>
<title id="l4">EVIDENCE ACT 1995 - SECT 136 General discretion to limit use of evidence</title>
<title id="l5">TRADE PRACTICES ACT 1974 </title>
<title id="l6">TRADE PRACTICES ACT 1974 No. 51, 1974 - SECT 52 Misleading or deceptive conduct.</title>
<title id="l7">TRADE PRACTICES ACT 1974 No. 51, 1974 - SECT 53 False representations.</title>
<title id="l8">FEDERAL COURT RULES 1979 </title>
</legistitles>
</case>